Matthias von Herrath

Company: Novo Nordisk

Job title: Senior Vice President & Chief Medical Officer

Seminars:

Targeted Biologics That Mobilize a Novel Regulatory cd8 T Cell Network to Reduce the Pathology of Human T Cell Driven Autoimmune Disease 5:00 pm

Review the modulation of a cytolytic regulatory CD8 T cell population that may prevent autoimmune driven inflammatory cascades Unveil the prevalence of CD8 Treg and their potential dysfunction across a spectrum of autoimmune disorders Discuss the introduction of targeted bispecific molecules that engage regulatory CD8 T cells, causing cytolytic elimination of pathogenic CD4 T cells…Read more

day: Day Two